<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="897">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654325</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201268</org_study_id>
    <secondary_id>2020-A02996-33</secondary_id>
    <nct_id>NCT04654325</nct_id>
  </id_info>
  <brief_title>Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients</brief_title>
  <acronym>COVIDEYE</acronym>
  <official_title>Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the prevalence of SARS-CoV-2 genome in patients with asymptomatic and moderately&#xD;
      symptomatic COVID19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients attending to the COVID19 screening facility of Paris South University hospital and&#xD;
      willing to participate to the study will have both nasopharyngeal and conjunctival swab for&#xD;
      SARS-CV-2 genome detection using PCR. The project will evaluate the prevalence of positive&#xD;
      conjunctival swabs in patients with positive nasopharyngeal swab. These results will be&#xD;
      corelated to symptoms of disease assessed with a standardized questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence of SARS-CoV-2 genome in tears</measure>
    <time_frame>at the end of the study, an average of 1 year</time_frame>
    <description>Prevalence of SARS-CoV-2 genome in tears</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence of systemic symptoms evaluated at the time of making an appointment by a systematic standardized interrogation</measure>
    <time_frame>at the end of the study, an average of 1 year</time_frame>
    <description>correlation between systemic symptoms (fever, chills, sweating, muscle aches, headache, runny or stuffy nose, cough, sore throat, asthenia, anosmia, agueusia, unusual shortness of breath, skin rash diarrhea, nausea vomiting) and positive conjunctival swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessement of viral load levels</measure>
    <time_frame>at the end of the study, an average of 1 year</time_frame>
    <description>correlation between nasopharyngeal viral load and conjunctival load (indirectly assessed with cycle thresholds quantification method)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1280</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Patients attending to the COVID19 screening facility</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. Study will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a stan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>conjunctival swab</intervention_name>
    <description>Patients will have conjunctival swab for SARS-CV-2 genome detection</description>
    <arm_group_label>Patients attending to the COVID19 screening facility</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving diagnostic nasopharyngeal PCR for COVID-19 as part of the usual&#xD;
             care&#xD;
&#xD;
          -  Age ≥ 18.&#xD;
&#xD;
          -  Information and signature of consent&#xD;
&#xD;
          -  Affiliated with a social security scheme or entitled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  Eye surgery less than 3 months old&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  No coverage through the health insurance system&#xD;
&#xD;
          -  Patient under judicial protection&#xD;
&#xD;
          -  Patient on AME&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Rousseau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine ROUSSEAU, PhD</last_name>
    <phone>33145212799</phone>
    <email>antoine.rousseau@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle Vauloup-Fellous, PhD</last_name>
    <phone>33145593724</phone>
    <email>christelle.vauloup-fellous@aphp.fr</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID19</keyword>
  <keyword>conjunctiva</keyword>
  <keyword>tears</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

